| 0.4799 0.019 (4.1%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.73 | 1-year : | 0.87 |
| Resists | First : | 0.62 | Second : | 0.75 |
| Pivot price | 0.53  |
|||
| Supports | First : | 0.43 | Second : | 0.35 |
| MAs | MA(5) : | 0.46 |
MA(20) : | 0.57 |
| MA(100) : | 0.92 |
MA(250) : | 1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 15.1 |
D(3) : | 13.5 |
| RSI | RSI(14): 33 |
|||
| 52-week | High : | 1.98 | Low : | 0.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CNTG ] has closed above bottom band by 33.2%. Bollinger Bands are 55.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.48 - 0.48 | 0.48 - 0.48 |
| Low: | 0.44 - 0.44 | 0.44 - 0.44 |
| Close: | 0.48 - 0.48 | 0.48 - 0.48 |
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Tue, 02 Apr 2024
Centogene N.V. Faces Nasdaq Compliance Challenge - TipRanks.com - TipRanks
Wed, 28 Feb 2024
Centogene faces Nasdaq delisting over market value shortfall - Investing.com
Fri, 16 Feb 2024
Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors - Simply Wall St
Wed, 26 Apr 2023
CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to ... - TradingView
Wed, 26 Apr 2023
Why Are Centogene Shares Trading Higher Today? - Yahoo Finance
Tue, 25 Apr 2023
Healthcare Stocks on the Move Tuesday: CNTG, PTPI, BXRX, APLT, INAB, ASRT, ARTL, ACON - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 9.6e+006 (%) |
| Held by Institutions | 2.7 (%) |
| Shares Short | 26 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.309e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -77.7 % |
| Operating Margin | -86.4 % |
| Return on Assets (ttm) | -27.7 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 5.071e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.7 |
| EBITDA (p.s.) | -1.12 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.28 |
| Price to Cash Flow | 0.7 |
| Dividend | 0 |
| Forward Dividend | 11870 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|